BCL6 and diffuse large B-cell lymphoma: Similarly, Bcl-6 antigen has been associated with good prognosis among patients treated with CHOP-like regimens, but not with CHOP-R16 or with sequential chemotherapy followed by ABMT in high-risk DLBCL cases.17